Eli Lilly's weight loss med tirzepatide gets endorsement from U.K.'s NICE
Hawkinsight
2024-12-25 09:06:37
1.09W
aprott/iStock via Getty Images
- The U.K.'s drug cost-effectiveness watchdog organization, the National Institute for Health and Care Excellence (\"NICE\"), has formally recommended Eli Lilly's (NYSE:LLY) GLP-1 tirzepatide as a treatment for weight loss.
- The drug is sold under the name Zepbound for weight loss
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
